Childhood myopia is more than just needing stronger glasses. It is a disease process that stretches the eye and raises the risk of serious conditions later in life. Today, parents have four proven ways to slow myopia progression: orthokeratology, multifocal soft contact lenses, low-dose atropine drops, and Stellest spectacle lenses.
Myopia rates have risen from 25% of Americans in the 1970s to more than 42% today. Studies show myopia prevalence climbs from about 15% in children ages five to seven, up to 59% by ages 17 to 19. High myopia, defined as greater than negative five diopters, increases nearly tenfold across the same age range.
Progressive myopia physically elongates the eye, stretching the delicate tissues inside. Moderate myopia carries a ninefold higher risk of retinal detachment, a tenfold higher risk of myopic macular degeneration, triple the risk of cataracts, and double the risk of glaucoma compared to eyes with normal vision.
When myopia reaches high levels beyond negative five diopters, the risks become even more severe. Retinal detachment risk jumps to 21 times higher, macular degeneration to 40 times higher, cataracts to five times higher, and glaucoma to three times higher.
Every additional diopter increases retinal detachment risk by about 30%, macular degeneration by about 67%, and glaucoma by about 20%. Slowing progression by just one diopter can reduce the risk of myopic maculopathy by around 40% and retinal detachment by roughly 30%.
Orthokeratology involves wearing custom rigid gas-permeable lenses overnight. While the child sleeps, these lenses gently reshape the cornea's curvature, temporarily correcting vision. Upon waking, the lenses are removed, and the child enjoys clear vision throughout the day without glasses or contacts. This reshaping also creates signals that slow the eye's growth.
Clinical trials including the ROMIO Study, LORIC Study, CRAYON Study, COOKI Study, and CONTROL Study have shown that ortho-k slows myopia progression by 36% to 56% compared to children wearing standard spectacles or contact lenses. More than one million people worldwide use orthokeratology regularly.
Ortho-k appeals particularly to active children, athletes, and swimmers who want freedom from daytime correction. Success depends on consistent nightly wear and proper lens care, making it best suited for responsible children and engaged families who can support the routine.
At Insight Vision Center Optometry, Dr. Nathan Schramm, OD, FSLS, FBCLA served as principal investigator for the Euclid Phoenix ortho-k trial, with Dr. Ariel Chen, OD serving as co-investigator. Customization options include wavefront-guided designs that optimize the optical profile for each eye.
Multifocal soft contact lenses designed for myopia control are worn during the day and discarded at night, offering a fresh lens every morning. The optical design features a central zone for clear distance vision surrounded by peripheral zones that create controlled myopic defocus. This defocus signals the eye to slow its growth.
MiSight 1 Day lenses are the first FDA-authorized contact lens clinically shown to slow myopia progression in children. Three-year clinical trials demonstrated a 59% reduction in refractive progression and a 52% reduction in axial length growth compared to children wearing single-vision lenses.
Child satisfaction rates are high. Studies show 90% of children prefer MiSight over glasses, and 90% can insert and remove the lenses on their own. Kids report seeing well during schoolwork, playing outdoors, and using screens.
These lenses suit children ages eight and older who are ready to handle daily lens insertion and removal responsibly. The daily disposable format minimizes infection risk and eliminates the need for cleaning solutions. They may be less convenient for certain water sports where lenses could be dislodged.
Low-dose atropine eye drops offer a non-optical approach to myopia management. At diluted concentrations of 0.01% to 0.05%, far lower than doses used for dilated eye exams, atropine slows axial elongation and myopia progression. Parents administer one drop nightly to each eye, making it one of the simplest treatment routines.
The ATOM2 Study demonstrated efficacy at low doses with minimal side effects. The LAMP Study, a randomized double-masked trial involving 350 children ages four to twelve, validated efficacy at various concentrations. Meta-analyses of randomized controlled trials involving thousands of children confirm that low-dose atropine typically reduces myopia progression by 50% to 60%.
The safety profile is excellent. Clinical trials found that some children experience mild light sensitivity in bright sunlight during the first few months, easily managed with sunglasses or hats. By the second year, most children reported no discomfort.
Atropine is particularly appealing for very young children under six who are not yet ready for contact lenses, for children with sensory sensitivities to lens wear, and for fast progressors who may benefit from combination therapy pairing atropine with an optical treatment.
Stellest spectacle lenses use H.A.L.T. technology, featuring 1,021 invisible microlenses arranged in rings around a clear central zone. The child looks through the clear center for sharp distance vision, while the surrounding lenslets create a volume of myopic defocus that signals the eye to slow its growth.
Clinical trials involving children ages six to twelve with myopia ranging from negative 0.75 to negative 4.50 diopters showed that Stellest wearers had 71% less refractive progression and 53% less eye-length growth compared to children wearing single-vision lenses over two years.
The key to success is consistent wear time. We recommend at least 10 hours per day, six days per week. Children who wear Stellest lenses 12 or more hours per day achieve maximum benefit. Longer daily wear correlates with better outcomes.
Stellest lenses are constructed from polycarbonate, a lightweight, impact-resistant material that offers 100% ultraviolet protection and includes an anti-smudge coating. This makes them safe for active kids. For contact or high-speed sports, some families keep a spare pair of single-vision glasses for the event, then resume Stellest immediately afterward.
Stellest lenses received FDA authorization under the De Novo pathway in September 2025, making them the first spectacle lens authorized specifically to help slow myopia progression in children.
Stellest lenses are well-suited for children ages six to twelve, particularly those who are not yet ready for contact lenses, who have sensory sensitivities, or who simply prefer glasses. Dr. Thanh Mai, OD, FSLS, FIAOMC serves on the EssilorLuxottica advisory board for Stellest and brings extensive experience fitting these lenses at Insight Vision Center Optometry.
Ortho-k offers the strongest appeal for active, athletic children who want complete freedom from daytime correction. Swimmers, gymnasts, soccer players, and outdoor enthusiasts benefit from waking up with clear vision. The treatment requires the highest level of lens care and responsibility, so it works best for children eight and older, or for younger children with highly engaged parents.
Multifocal soft contact lenses like MiSight provide daytime freedom similar to ortho-k but with the convenience of a disposable lens. No overnight wear, no cleaning solutions. These lenses suit responsible children ages eight and older who want the benefits of contact lenses but prefer not to sleep in lenses.
Low-dose atropine remains the simplest intervention from a physical handling perspective. It is often the first choice for very young children under six, for kids with contact lens intolerance, or as an add-on therapy for children whose myopia progresses quickly. Because it does not correct vision, children still need daytime glasses or contacts.
Stellest lenses offer notable simplicity. Children ages six to twelve who already wear glasses can transition to Stellest without learning new skills. For families with young children, those with sensory sensitivities, or those seeking the least disruption, Stellest is often the most practical choice.
For children whose myopia progresses rapidly despite a single treatment, we may consider pairing Stellest with low-dose atropine, or transitioning to ortho-k at night while using Stellest as backup daytime correction. This layered approach maximizes benefit for fast progressors.
Children in treatment typically return for progress checks every six months. We measure visual acuity, refraction, and axial length using instruments like the Zeiss AXL WAVE Optical Biometer. If progression continues faster than expected despite good compliance, the treatment plan may be strengthened.
A child might start with Stellest at age six, transition to MiSight at age ten when ready for lens handling, and later move to ortho-k if they become serious about sports. The key is working with a practice experienced in all options who can adjust the plan based on the child's evolving needs.
Natural light triggers dopamine release in the retina, which signals the eye to slow elongation. Research suggests that at least 90 to 120 minutes per day outdoors provides protective benefit. The intensity and spectrum of natural light, not just physical activity, deliver this effect.
The 20-20-20 rule recommends that every 20 minutes spent on near work, children should look at something at least 20 feet away for 20 seconds. Balancing screen time with outdoor time, ensuring good lighting during close work, and encouraging breaks during homework all support healthier visual development. Our children's vision symptom checker can help you identify early signs of visual stress.
The younger a child is when myopia begins, the more years remain for progression. A child who becomes myopic at age six has six to eight years of active eye growth ahead, potentially accumulating several diopters by late adolescence. Each additional diopter compounds lifetime disease risk.
Waiting is not neutral. Every year of delay costs diopters and increases risk. Children with progressive myopia are on a trajectory toward higher prescriptions unless treatment begins. Starting when myopia is still mild preserves more of the eye's natural structure.
Insight Vision Center Optometry offers all four myopia management treatments. Dr. Thanh Mai, OD, FSLS, FIAOMC serves as VP of Clinical Innovation for Treehouse Eyes and sits on the EssilorLuxottica advisory board for Stellest. Dr. Nathan Schramm, OD, FSLS, FBCLA served as principal investigator for the Euclid Phoenix ortho-k trial.
We use the Zeiss AXL WAVE Optical Biometer and Pentacam for precise axial length tracking and corneal mapping. These tools allow us to monitor treatment response accurately and adjust protocols as needed.
Insight Vision Center Optometry is affiliated with Treehouse Eyes, a national program focused on slowing childhood myopia. Dr. Nhi Nguyen, OD has Treehouse Eyes affiliation and follows structured protocols and outcome tracking to help optimize results for every child.
Children can begin treatment as soon as myopia is detected and shows signs of progression. For Stellest glasses and atropine, children as young as six are good candidates. Contact lens options like MiSight and ortho-k typically work best for children ages eight and older who can handle lens insertion responsibly.
Most children continue myopia management throughout their active growth years, typically until their mid to late teens. Progression naturally slows as children approach adulthood. Your eye doctor will monitor progress and adjust or taper treatment based on stabilization patterns.
Yes. Ortho-k provides complete freedom from daytime correction, making it well-suited for athletes. Children wearing Stellest glasses can use a backup pair of single-vision glasses or contacts for high-impact sports. MiSight contact lenses work well for most activities except water sports where lenses could be dislodged.
Side effects are generally mild across all treatments. Atropine may cause temporary light sensitivity managed with sunglasses. Contact lens options require proper hygiene to prevent infection. Stellest glasses have no known side effects beyond normal adjustment to new lenses.
If your child's myopia continues progressing faster than expected, your eye doctor may recommend intensifying treatment. Options include increasing atropine concentration, switching to a different lens modality, or combining treatments. Regular six-month monitoring catches these situations early.
Myopia management treatments are often considered premium services not fully covered by standard vision insurance. Many families use Health Savings Accounts or Flexible Spending Accounts to offset costs. Insight Vision Center Optometry offers complimentary initial consultations to help families understand their options.
